MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-08-2022
Albireo Pharma ROCE Ratio 2011-2026 | ALBO
Annual ROCE Ratio Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -70.32 | -36.98 | -41.82 | -21.95 | -37.64 | -52.13 | -49.9 | -80.9 | -53.2 | -50.32 | -60.77 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -21.95 | -80.9 | -50.54 |
Quarterly ROCE Ratio Albireo Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -94.05 | -115.62 | -102.55 | -98.92 | -77.56 | -92.51 | -85.9 | -66.85 | -41.31 | -63.46 | -70.66 | -77.01 | -55.02 | -65.35 | -53.53 | -45.61 | -19.29 | -29.3 | -28.99 | -30.63 | -29.49 | -38.79 | -38.08 | -22.7 | -11.15 | -11.15 | -1.85 | -7.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.85 | -115.62 | -52.66 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
14.97 | $ 20.22 | -2.32 % | $ 2.55 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
-188.87 | $ 164.71 | -1.01 % | $ 8.19 B | USA |
 |
AbCellera Biologics
ABCL
|
-16.8 | $ 3.73 | -2.49 % | $ 1.11 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
14.24 | $ 8.5 | -2.63 % | $ 1.39 B | Britain |
 |
Catalyst Pharmaceuticals
CPRX
|
27.01 | $ 23.88 | - | $ 2.92 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-60.51 | $ 18.08 | 1.06 % | $ 868 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Certara
CERT
|
1.98 | $ 7.19 | 1.93 % | $ 1.15 B | USA |
 |
Eton Pharmaceuticals
ETON
|
-7.7 | $ 17.72 | -2.37 % | $ 454 M | USA |
 |
Exelixis
EXEL
|
40.35 | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.41 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Galapagos NV
GLPG
|
-3.51 | $ 33.13 | -2.82 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
-631.87 | $ 27.7 | 1.12 % | $ 361 M | USA |
 |
Genmab A/S
GMAB
|
31.74 | $ 27.67 | -6.69 % | $ 17.7 B |  Danmark |
 |
Capricor Therapeutics
CAPR
|
-87.67 | $ 26.04 | -3.07 % | $ 697 M | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-87.44 | $ 0.99 | -2.92 % | $ 72.7 M | USA |
 |
Halozyme Therapeutics
HALO
|
960.8 | $ 69.39 | -0.67 % | $ 8.32 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
20.45 | $ 28.56 | -1.19 % | $ 1.64 B | USA |
 |
ImmuCell Corporation
ICCC
|
-4.03 | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-180.78 | - | -10.17 % | $ 12.2 K | USA |
 |
Immuron Limited
IMRN
|
-12.29 | $ 0.75 | -0.69 % | $ 6.43 M |  Australia |
 |
Immatics N.V.
IMTX
|
1.74 | $ 9.86 | -1.3 % | $ 620 M | Germany |
 |
Immunic
IMUX
|
1572.16 | $ 1.1 | 3.3 % | $ 171 M | USA |
 |
Immunovant
IMVT
|
-70.24 | $ 26.99 | -2.74 % | $ 4.09 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Inhibrx
INBX
|
-503.92 | $ 75.96 | -1.97 % | $ 3.58 B | USA |
 |
InMed Pharmaceuticals
INM
|
-65.74 | $ 0.75 | -8.49 % | $ 1.84 M | Canada |
 |
INmune Bio
INMB
|
-79.65 | $ 1.41 | 6.07 % | $ 25.4 M | USA |
 |
Insmed Incorporated
INSM
|
-168.72 | $ 146.89 | 0.39 % | $ 29.2 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-28.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
99.51 | $ 3.19 | -4.49 % | $ 1.14 M | USA |
 |
Innate Pharma S.A.
IPHA
|
0.41 | $ 1.63 | -1.21 % | $ 235 M | France |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-39.57 | $ 29.11 | -0.31 % | $ 1.69 B | USA |